SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001651308-23-000137
Filing Date
2023-09-19
Accepted
2023-09-19 06:01:40
Documents
12
Period of Report
2023-09-17
Items
Item 1.02: Termination of a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K bgne-20230917.htm   iXBRL 8-K 37505
  Complete submission text file 0001651308-23-000137.txt   165753

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT bgne-20230917.xsd EX-101.SCH 1901
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT bgne-20230917_lab.xml EX-101.LAB 24751
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT bgne-20230917_pre.xml EX-101.PRE 13019
6 EXTRACTED XBRL INSTANCE DOCUMENT bgne-20230917_htm.xml XML 2866
Mailing Address C/O MOURANT GOVERNANCE SERVICES (CAYMAN) 94 SOLARIS AVENUE, CAMANA BAY GRAND CAYMAN E9 KY1-1108
Business Address C/O MOURANT GOVERNANCE SERVICES (CAYMAN) 94 SOLARIS AVENUE, CAMANA BAY GRAND CAYMAN E9 KY1-1108 13459494123
BeiGene, Ltd. (Filer) CIK: 0001651308 (see all company filings)

IRS No.: 981209416 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37686 | Film No.: 231262431
SIC: 2834 Pharmaceutical Preparations